Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials
Open Access
- 7 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in The Journal of Headache and Pain
- Vol. 22 (1), 1-11
- https://doi.org/10.1186/s10194-020-01212-4
Abstract
Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, including the fully humanized monoclonal antibody (IgG2Δa) fremanezumab, have demonstrated safety and efficacy for migraine prevention. Clinical trials include responders and nonresponders; efficacy outcomes describe mean values across both groups and thus provide little insight into the clinical benefit in responders. Clinicians and their patients want to understand the extent of clinical improvement in patients who respond. This post hoc analysis of fremanezumab treatment attempts to answer this question: what is the benefit in subjects who responded to treatment during the two, phase 3 HALO clinical trials? We included subjects with episodic migraine (EM) or chronic migraine (CM) who received fremanezumab quarterly (675 mg/placebo/placebo) or monthly (EM: 225 mg/225 mg/225 mg; CM: 675 mg/225 mg/225 mg) during the 12-week randomized, double-blind, placebo-controlled HALO EM and HALO CM clinical trials. EM and CM responders were defined as participants with a reduction of ≥ 2 or ≥ 4 monthly migraine days, respectively. Treatment benefits evaluated included reductions in monthly migraine days, acute headache medication use, and headache-related disability, and changes in health-related quality of life (HRQoL). Overall, 857 participants from the HALO trials were identified as responders (EM: 429 [73.8%]; CM: 428 [56.7%]). Reductions in the monthly average number of migraine days were greater among EM (quarterly: 5.4 days; monthly: 5.5 days) and CM (quarterly: 8.7 days; monthly: 9.1 days) responders compared with the overall population. The proportion of participants achieving ≥ 50% reduction in the average monthly number of migraine days was also greater in responders (EM: quarterly, 59.8%; monthly, 63.7%; CM: quarterly, 52.8%; monthly, 59.0%) than in the overall population. Greater reductions in the average number of days of acute headache medication use, greater reductions in headache-related disability scores, and larger improvements in HRQoL were observed among EM and CM responders compared with the overall populations. Fremanezumab responders achieved clinically meaningful improvements in all outcomes. The magnitude of improvements with fremanezumab across efficacy outcomes was far greater in responders than in the overall trial population, providing insight into expected treatment benefits in participants who respond to fremanezumab in clinical practice. ClinicalTrials.gov identifiers: NCT02629861 (HALO EM) and NCT02621931 (HALO CM).Funding Information
- Teva Pharmaceutical Industries, Petach Tikva, Israel.
This publication has 25 references indexed in Scilit:
- Preventive Migraine TreatmentCONTINUUM: Lifelong Learning in Neurology, 2015
- Validation of the Headache Impact Test (HIT-6) in patients with chronic migraineHealth and Quality of Life Outcomes, 2014
- Medication-overuse headache: epidemiology, diagnosis and treatmentTherapeutic Advances in Drug Safety, 2014
- Clinical Aspects of Medication Overuse HeadachesHeadache: The Journal of Head and Face Pain, 2013
- Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS‐II)Headache: The Journal of Head and Face Pain, 2013
- Validating Migraine‐Specific Quality of Life Questionnaire v2.1 in Episodic and Chronic MigraineHeadache: The Journal of Head and Face Pain, 2011
- Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: A systematic reviewCephalalgia, 2011
- Guidelines for Controlled Trials of Prophylactic Treatment of Chronic Migraine in AdultsCephalalgia, 2008
- Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact TestJournal of Clinical Epidemiology, 2006
- Clinical Utility of an Instrument Assessing Migraine Disability: The Migraine Disability Assessment (MIDAS) QuestionnaireHeadache: The Journal of Head and Face Pain, 2001